TrialSafety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
Trial details
- Registry ID
- NCT06465108
- Phase
- Phase 2
MBX
MBX Biosciences
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
13Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismNCT06465108 | MBX Biosciences | Phase 2 | Completed | 2025-05-23Actual |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With HypoparathyroidismNCT06531941 | MBX Biosciences | Phase 2 | Active not recruiting | 2027-05-27Estimated |
| Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)NCT07029412 | MBX Biosciences | Phase 2 | Completed | 2026-04-18Actual |
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
Trial details
- Registry ID
- NCT06531941
- Phase
- Phase 2
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
Trial details
- Registry ID
- NCT07029412
- Phase
- Phase 2
Latest recorded trial changes
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
NCT07029412 · MBX Biosciences
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 10; type: ESTIMATED
+ Updated value
count: 20; type: ACTUAL
Completion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2025-12-22
+ Updated value
2026-04-18
Recruitment status
Recorded edit− Previous value
Recruiting
+ Updated value
Completed
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
NCT07029412 · MBX Biosciences
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following 2 different dose levels of MBX 1416.
+ Updated value
measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416.
The saved outcome text may be shortened. Check the source for full wording.
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
NCT06465108 · MBX Biosciences
Completion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2025-05
+ Updated value
2025-05-23
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Completed
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941 · MBX Biosciences
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 48; type: ESTIMATED
+ Updated value
count: 60; type: ACTUAL
Recruitment status
Recorded edit− Previous value
Recruiting
+ Updated value
Active not recruiting
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
NCT07029412 · MBX Biosciences
Recruitment status
Recorded edit− Previous value
Not yet recruiting
+ Updated value
Recruiting